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Update on anticoagulation 
agents and reversals
Carolyn M. Ruiz Rodríguez
PGY-1 Pharmacy Resident
West Kendall Baptist Hospital
Abbreviations
 Acute Coronary Syndrome 
(ACS)
 Activated prothrombin 
complex concentrate (aPCC)
 Body mass index (BMI)
 Coronary artery disease 
(CAD)
 Deep vein thrombosis (DVT)
 Direct oral anticoagulants 
(DOAC)
 Gastrointestinal (GI)
 Hip fracture surgery (HFS)
 Intracranial hemorrhage 
(ICH)
 Low molecular weight heparin 
(LMWH)
 Myocardial infarction (MI)
 Non-valvular atrial fibrillation 
(NVAF)
 Peripheral artery disease 
(PAD)
 Prothrombin complex 
concentrate (PCC)
 Pulmonary embolism (PE)
 Total hip arthroplasty (THA)
 Total knee arthroplasty (TKA)
 Unfractionated heparin (UFH) 
 Venous thromboembolism  
(VTE)
 Vitamin K antagonist (VKA)
2
Objectives 
1. Review direct oral anticoagulants (DOACs)
2. Discuss the place in therapy for DOACs
3. Describe agents available for the reversal 
of bleeding associated with the use of 
DOACs
4. Define the pharmacist’s role in the 















Dalteparin (Fragmin®) Direct Factor Xa 
Inhibitors
Fondaparinux (Arixtra®) Rivaroxaban (Xarelto®)
Low Molecular Weight 
Heparin (LMWH)
Apixaban (Eliquis®)
Enoxaparin (Lovenox®) Edoxaban (Savaysa®)
Betrixaban (Bevyxxa®) 
Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL.
Anticoagulation Cascade
 Warfarin
 Inhibits vitamin K 
and factors VII, IX, 
X, IIa
 Dabigatran




 Inhibit factor Xa
Gomez A, et al. Vasc Health Risk Manag. 2013. 5
Direct Oral Anticoagulants (DOACs)

































(elderly 11-12) 9-14 10-14 19-27 
Frequency Once daily Once daily Twice daily Once daily Once daily
Renal 
excretion 80 % 33 % 25 % 35-50 % 18 %
NVAF-non-valvular atrial fibrillation; VTE-venous thromboembolism; CAD-coronary artery disease;
PAD-peripheral artery disease
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):380-6. 
Bevyxxa (betrixaban), Savayza (edoxaban) prescribing information. 6
DOACs Compared to 
Warfarin
Lawrence, LK. Direct oral anticoagulants and parenteral direct thrombin inhibitors, 
UpToDate, Waltham, MA, 2018. 7
Advantages Disadvantages
As effective as warfarin Expensive





hemorrhage (ICH) Shorter half-lives 
No monitoring required Limited ability to assess effectiveness
No diet restrictions Limited data in end-stagerenal/hepatic impairment
Less drug interactions Costly antidote
ICH with DOACs
 Incidence varies between 0.6% to 1%
 VTE treatment
 52% reduction in ICH compared with 
warfarin
 Van Der Hulle, et al (2014)
•Meta-analysis of 5 trials (n=24,555)
•Non-fatal ICH 
 DOACs 0.09% vs. warfarin 0.25%
Ruff CT, et al. Lancet 2014;383(9921):955-962.
Van Der Hulle T, et al. J Thromb Haemost, 2014. 8
ICH with DOACs
 AF
 Lower risk of ICH for the treatment of 
stroke prevention  
9
Connolly SJ, et al. N Engl J Med. 2009; Patel MR, et al. N Engl J Med. 2011; Giugliano RP, et al. 
N Engl J Med. 2013; Granger CB, et al. N Engl J Med. 2011; Ruff CT, el al. Lancet. 2014. 
DOAC vs. warfarin Percentage (%)
Rivaroxaban 0.80 vs. 1.2
Apixaban 0.33 vs. 0.80
Edoxaban 0.39 vs. 0.85
Dabigatran 0.10 vs. 0.39
GI Bleeding with DOACs
 DOACs associated with 25—30% increased 
risk when compared to warfarin
 Apixaban has shown to have a favorable profile
 Rivaroxaban associated with highest risk 
among DOACs
10
Abraham NS, et al. Gastroenterology. 2017;152:1014-1022. 
Graham DJ, et al. Circulation. 2015;131(2):157-164. 
Apixaban vs. dabigatran Apixaban vs. rivaroxaban
1.38 vs. 2.73 %/year 1.34 vs. 3.54 %/year
P < 0.001 P < 0.001
GI Bleeding with DOACs
 Rate of GI bleeding increases with age 
among patients using DOACs
 Higher risk in patients 65 years or older
 Co-therapy with proton pump inhibitors 
(PPI) or H2 antagonists has shown to 
reduce the incidence of GI bleed
11
Abraham NS, et al. BMJ. 2015;350:1857. 




1. Prophylaxis of Venous 
Thromboembolism (VTE)
2. Treatment of VTE
3. Non-valvular Atrial Fibrillation (AF)
4. Acute Coronary Syndrome (ACS) 
13
VTE Prophylaxis in Medical 
Patients
 CHEST Guidelines (2012)
 Recommended agents for at risk patients
• LMWH, UFH, fondaparinux, intermittent 
pneumatic compression and/or graduated 
compression stockings
• Limited guidance on DOACs
 Betrixaban (Bevyxxa®) is the only FDA 
approved DOAC for medical VTE 
prophylaxis
Gould MK, et al. CHEST. 2012. 14
VTE Prophylaxis in Medical 
Patients
 American Society Hematology (ASH) 
recommendation (2018) 




 Inpatient only treatment recommended,
rather than inpatient plus extended 
duration outpatient 
Schunemann HJ, et al. Blood Advances. 2018. 15
VTE Prophylaxis in Surgical 
Orthopedic Patients
 Total hip arthroplasty (THA) or total knee 
arthroplasty (TKA) 
Treatment duration—Minimum 10 to 14 days
Falck-Ytter, et al. CHEST. 2012.
• LMWH • Heparin 
• Fondaparinux • Rivaroxaban 
• Warfarin • Dabigatran
• Aspirin • Apixaban
16
VTE Prophylaxis in Surgical 
Orthopedic Patients
 Hip fracture surgery (HFS)
 DOACs not recommended 
Treatment duration—Minimum 10 to 14 days
Falck-Ytter, et al. CHEST. 2012. 17
• LMWH • Warfarin
• Heparin • Aspirin
• Fondaparinux
Aspirin Role in VTE Prophylaxis 
in Surgical Patients
 Bawa, et al. (2018) 
 Retrospective review of post-op medication claims of 
patients who received aspirin, warfarin or enoxaparin 
within 6 months of THA and TKA 
 DVT rates
• Aspirin 2.20%, warfarin 4.74%, enoxaparin 3.73% 
 Anderson, et al. (2018)
 Compared rivaroxaban 10 mg PO daily for 5 days 
followed by aspirin 81 mg PO daily versus 
rivaroxaban
 VTE occurrence
• Aspirin/rivaroxaban 0.64% vs. 0.70% rivaroxaban alone 
(p<0.001)
Anderson DR, et al. N Engl J Med. 2018.
Bawa H, et al. J Am Acad Orthop Surg. 2018.
18
VTE Prophylaxis in General 
Surgical Patients
 CHEST Guidelines (2012)
 General and abdominal-pelvic surgery 
• Low risk of VTE
 Mechanical over pharmacological prophylaxis
• Moderate and high risk of VTE in patients with 
low risk of bleeding
 Unfractionated heparin
 LMWH
• High risk of VTE and high risk of bleeding
 Mechanical prophylaxis  
DOACs not recommended
Gould MK, et al. CHEST, 2012; 141 (2):e227S-e277S. 19
VTE Prophylaxis Dosing
Name Dose
Heparin 5000 units subQ Q12h (low risk)Q8h (high risk)
Enoxaparin 40 mg subQ Q24h30 mg Q24h (renal impairment)
Dabigatran 220 mg PO daily (hip surgery only)
Rivaroxaban 10 mg PO daily (hip or knee surgery only)
Apixaban 2.5 mg PO twice daily(hip or knee surgery only)
Betrixaban 160 mg PO on day 1 then 80 mg PO daily 
20Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL.
VTE TREATMENT
VTE Treatment







 DOACs preferred over warfarin (except 
betrixaban)
Kearon C, et al. CHEST, 2016.
Xarelto (rivaroxaban) & Eliquis (apixaban) prescribing information. 22
Can be given without initial 
parenteral anticoagulation 
(in hemodynamically stable pts 
without extensive clot burden)
VTE Treatment
Kearon C, et al. CHEST, 2016. 23
Type Duration of therapy
Proximal provoked VTE 3 months
Isolated distal DVT 3 months
Unprovoked VTE 3 months
First unprovoked VTE • Extended treatment
(low-moderate risk of bleeding)




Independent of risk of bleeding
Extended treatment – no stop date
VTE Extended Treatment 
with Aspirin
 CHEST Guidelines (2016)
 Recommend aspirin to prevent recurrence 
of VTE
• Dose: 100 mg once daily (low dose)
• Criteria:
 Unprovoked proximal DVT/PE
 No contraindication to aspirin use
 Stopped oral anticoagulation or completed 
anticoagulation treatment
 Low risk of bleeding
Kearon C, et al. CHEST, 2016. 24
VTE Treatment in Special 
Population 
 CHEST Guidelines (2016)
 Cancer
• LMWH recommended over warfarin or 
DOACs (long term therapy)
 Pregnancy
• LMWH recommended
• Duration of therapy: 3 to 6 months
• Not recommended:
 DOACs (insufficient safety information)
 Warfarin 
 Fondaparinux
Kearon C, et al. CHEST, 2016. 
Bates AM, et al. CHEST, 2016. 25
VTE Treatment Dosing 
(Initial)
 Enoxaparin 1mg/kg subQ Q12h 
(reduce to Q24h in renal impairment)
 Alternative: 1.5 mg/kg subQ Q24h 
 Fondaparinux 5 – 10 mg subQ daily 
 Dependent on weight
 Heparin infusion
 80 units/kg IV bolus then 18 units/kg/h 
infusion 
26Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL.
VTE Treatment Dosing
 Rivaroxaban 15 mg PO Q12h for 21 days 
followed by 20 mg PO daily 
 Apixaban 10 mg PO Q12h for 7 days 
followed by 5 mg PO Q12h
 Dabigatran 150 mg PO Q12h*
 Edoxaban 60 mg PO Q24h (>60 kg)*
30 mg PO Q24h (≤60 kg)*
*At least 5 days of initial therapy with parenteral anticoagulation





Stroke Prevention in AF
 DOACs shown to be at least as safe and 
effective as warfarin for the prevention of 
stroke and systemic embolism
 Reduced events by 19% compared to 
warfarin (p<0.0001)
 Safety
Lip GYH, et al. CHEST, 2018.
Ruff CT, et al. Lancet. 2014. 29
Major Bleeds Reduced by 14% (p=0.06)
Intracranial 
hemorrhage
Reduced by 52% (p<0.0001)
GI Bleeds Increased (p=0.04)
Assessment Tools in AF
 CHADS2 CHA2DS2—VASc
 Used to determine stroke risk
 HAS—BLED score
 Developed originally for warfarin 
 Predicts serious bleeding
• Only score predictive of intracranial bleeding
Both scores complement each other
Lip GYH, et al. CHEST, 2018; 154(5):1121-1201.  
Ruff CT, et al. Lancet, 2014;383(9921):955-962. 30
Stroke Risk Assessment Tool
CHA2DS2—VASc
 Congestive Heart Failure  
 Hypertension 




 Age (> 65 years)
 Sex (Female)




1 female Low None 
≥ 1 male
≥ 2 female Moderate
No therapy or 
DOAC or 
warfarin
≥ 2 Moderate or High
DOAC or
warfarin
Lip GYH, et al. CHEST, 2018; 154(5):1121-1201.
Bleeding Risk Assessment 
Tool
 HAS—BLED used to 
address modifiable 
bleeding risk factors










(i.e. gastric ulcer disease)
1 point
Labile INR 1 point 
Age 1 point
Drugs 
(i.e NSAIDs or aspirin)
1 point
Score >3 (high risk): warrant 
more frequent monitoring 
Lip GYH, et al. CHEST, 2018; 154(5):1121-1201. 32
AF Treatment
CHEST Guidelines (2018)
 Treatment of choice
 DOACs over warfarin (strong 
recommendation)
 Prior unprovoked bleeding, warfarin-





Lip GYH, et al. CHEST, 2018; 154(5):1121-1201. 33
AF Treatment in Mechanical 
Heart Valves
 DOACs not recommended–limited studies
 RE-ALIGN trial (n=252)
 Studied dabigatran vs. warfarin 
• Stroke occurrence: 5% vs. 0%
• Bleeding: 27% vs. 12% (p<0.01)
• Study terminated prematurely due to safety 
concerns
 Treatment of choice: LMWH or UFH until 
stable on warfarin
Whitlock RP, et al. CHEST. 2012. 
Eikelboom JK, et al. N Engl J Med. 2013. 
Nishimura RA, et al. JACC. 2017. 34
AF Treatment in Elderly
 Age increases risk of intracranial 
hemorrhage (ICH) and mechanical falls 
Study Methods Findings
Sardar, et al. 
(2014)
• Meta-analysis of pts ≥75 yo
• Compared DOACs 
(rivaroxaban, apixaban and 
dabigatran) vs. warfarin
DOACs:
• No excess bleeding 
• Equal or greater efficacy
Chao, et al. 
(2018)
• Cohort study in the very 
elderly (≥90 yo)
• Evaluated the risk of ICH 
and stroke in patients in 2 
groups (DOACs vs. warfarin)
Risk of ICH:
• DOACs 0.42% vs. warfarin 
1.63%; p<0.044)
Chao TF, et al. Circulation. 2018;138:37-47. 
Sardar P, et al. J Am Geriatr Soc. 2014 May;62(5):857-64. 35
AF Treatment in Elderly
 Risk of falls
 Individual risk assessment prior to starting 
DOACs
 A patient would have to fall 295 times per 
year for the risk from falls to outweigh the 
benefits of anticoagulation
 Conclusion
 DOACs rarely considered a contraindication
Fear the clot, not the bleed
Man-Son-Hing M, et al. Arch Intern Med. 1999.
Sardar P, et al. J Am Geriatr Soc. 2014. 
Lip GYH, et al. CHEST. 2018. 36
AF Treatment in End-Stage 
Renal Disease (ESRD)
 Dias, et al. (2016)
 Rivaroxaban (15 mg PO daily)
• Single-dose study resulted in similar 
exposure to patients studied who had     
CrCl 15 to 49 mL/minute
 Siontis, et al. (2018)
 Apixaban (5 mg PO twice daily) 
• Lower risk of stroke, major bleeding and 
death vs. VKA
 Limited studies available– use with caution
Dias C, Moore KT, et al. Am J Nephrol. 2016;43(4):229-236.  
Siontis KC, et al. Circulation. 2018;138:1519-1529. 37




 Treatment of choice: LMWH Q12h
 Avoid use of DOACs
 Breast feeding
 Use LMWH, unfractionated heparin, or 
warfarin
 DOACs not recommended
Kearon C. et al. CHEST. 2016; 149:315-52.
Lip GYH. Et al. CHEST. 2018; 154 (5): 1121-1201. 38
AF Treatment in Obese 
Patients
 International Society of Hemostasis 
and Thrombosis (2016) Guidelines
 Patients with BMI >40 kg/m2 or >120 kg
•Limited clinical data available
•Warfarin preferred agent
•DOACs not recommended
 No FDA approved dosage recommendation
39Martin K, et al. J Thromb Haemost. 2016;14(6):1308-1313.
Treatment Based on Patient 
Characteristics




apixaban, dabigatran, edoxaban, 
rivaroxaban
High risk of GI bleeding apixaban, dabigatran
Major GI symptoms or dyspepsia apixaban, rivaroxaban, edoxaban
High risk of bleeding** apixaban, dabigatran, edoxaban
Low pill burden edoxaban, rivaroxaban, warfarin
TIA-transient ischemic attack; GI-gastrointestinal
*CrCl 15-49 mL/min
**Defined as a HAS-BLED of ≥3 points
40Lip GYH, et al. CHEST. 2018; 154(5):1121-1201.
AF Treatment Dosing 
Name Dose Renal impairment
Acute treatment
Enoxaparin 1 mg/kg subQ Q12h 1 mg/kg subQ Q24h
Chronic treatment 
Warfarin Dose to INR goal of 2-3 No dose adjustment
Aspirin 75—100 mg PO daily No dose adjustment
Acute and chronic treatment
Apixaban 5 mg PO Q12h 2.5 mg PO Q12h
Rivaroxaban 20 mg PO daily 15 mg PO daily 
Dabigatran 150 mg PO Q12h 75 mg PO Q12h





ATLAS ACS 2–TIMI 51 Trial 
 Compared placebo vs. rivaroxaban 2.5 mg 
PO Q12 h vs. rivaroxaban 5 mg PO Q12 h
 Conclusion 
 Reduced death from cardiovascular causes, MI, 
or stroke (rivaroxaban 8.9 vs. placebo 10.7%; 
p<0.008)
 Rivaroxaban 2.5 mg PO twice daily may be 
considered in patients with low risk of bleeding 
not requiring chronic anticoagulation for other 
indications








Perioperative Bleeding Risk 
Assessment















devices and catheter 
ablation)








surgeries (i.e. joint 
arthroplasty)
Burnett AE, et al. J Thromb Thrombolysis. (2016) 41:206–232. 46
Perioperative Bleeding Risk 
Assessment
Calculated CrCl 
(mL/min) Timing of Last Dose Before Surgery
Low Risk of Bleeding High Risk of Bleeding
Dabigatran
> 50 Minimum 24 hours 2 days
31-50 2 days 5 days
< 30 4 days 5-6 days
Rivaroxaban, apixaban, edoxaban
> 50 1 day 2 days
31-50 1-2 days 3-4 days
< 30 2 days 4 days
Anticoagulation Therapy 2nd edition. ASHP; 2018 47
When to Restart DOACs?
Delay until adequate hemostasis
Burnett AE, et al. J Thromb Thrombolysis (2016) 41:206–232. 48
Procedural Bleed Risk DOAC Resumption time
Minimal May not require interruption of DOAC therapy
Low 24 hours post-operative














General Measures of 
Bleeding
 Assessment: 
 Determine the urgency of event
 Assess the risk of bleeding and thrombosis
 Obtain accurate medication history
 Discontinue/hold anticoagulation
 Provide supportive measures
 Pharmacological intervention 
 Specific reversal agents 
 Replace blood losses





Fondaparinux No specific reversal 
Fresh Frozen Plasma (FFP); PCC (Kcentra®); 
Recombinant Factor VIIa
Warfarin Vitamin K (Mephyton®)—PO or IV
FFP; PCC (Kcentra®); Recombinant Factor VIIa
Dabigatran Idarucizumab (Praxbind®) 
aPCC (FEIBA®)
Activated charcoal (within 2 h of ingestion)





Activated charcoal (within 2 h of ingestion)
Antifibrinolytic (i.e. tranexamic acid)
53UpToDate. Waltham, MA, 2018.
Management of ICH
 American Heart Association/American 
Stroke Association Guidelines (2015)
 Dabigatran, rivaroxaban or apixaban 
induced
• Activated PCC or other type of PCC
• Activated charcoal if last dose within <2 hrs
 Optimal time to resume anticoagulation
• 4 weeks (reduces risk of ICH recurrence)
 Exception: patients with mechanical heart 
valves
Hemphill III JC, et al. Stroke. 2015; 46:2032-2060. 54
Management After GI Bleed 
 Based on available evidence
 Warfarin may be restarted 7 to 14 days 
following a GI bleed
 DOAC resumption after a GI bleed
• Data is limited, consider the following
 Faster onset of action
• Delay restarting therapy for a few more days 
(compared to warfarin)
 Select DOAC with less GI bleed risk (i.e. 
apixaban)
Abraham NS, et al. Gastroenterology. 2017;152:1014-1022. 55
Reversal of DOAC with Prothrombin 
Complex Concentrates (PCC)
 Plasma derived products of human clotting 
factors
 Preferred non-hemostatic agent for DOAC 
reversal
 Weight based dosing more effective than 
standard dosing
 Adverse effect– hypercoagulability
Kcentra (4FPCC), Profilnine (3FPCC), Feiba (aPCC) prescribing information. 56
Reversal of DOAC with PCC
Types Factors Dosage (units/kg) Target Cost
4 factor PCC 
(Kcentra®)
II (prothrombin),




















PCC (Feiba®) II, VIIa, IX and X
• ICH: 50
• Life threating 
bleed:25 to 100
(off label use)
dabigatran $3,100 to 11,630*
*Assuming 70 kg patient, and recommended dose range
*Based on hospital acquisition cost
Kcentra (4FPCC), Profilnine (3FPCC), Feiba (aPCC) prescribing information. 
Tomaselli GF, et al. JACC. 2017;70(24)3042-67. 57
Reversal of DOAC with PCC
Low grade evidence
 Indications
 Use only in life-threatening circumstances 
or urgent surgery/procedures
 PCC recommended over aPCC
 Higher incidence of thrombosis with aPCC
58Garcia DA, Management of bleeding in patients receiving DOACs, UpToDate. Waltham, MA, 2018.
When to Use PCC?
 First line agent
 Apixaban, edoxaban and rivaroxaban
 4 factor-PCC most extensively studied 
 Second line agent
 Dabigatran
• Reversal agent not available
• Use aPCC
 May consider PCC 
59Tomaselli GF, et al. JACC. 2017;70(24)3042-67.
Idarucizumab (Praxbind®)
 Humanized monoclonal antibody fragment 
(Fab)
 First line agent for reversal of dabigatran 
(Pradaxa®)
 Binds irreversibly to free and thrombin-
bound dabigatran
 Onset of action: reverses within 10 minutes 
of administration
Praxbind (idarucizumab) prescribing information. 60
Idarucizumab (Praxbind®)
 Supplied: 2.5 g/50 mL ($2,100 per dose*)
 Administration (within 1 hr of removal 
from vial)
61





2.5 g IV 
bolus over 
5-10 min
Consider additional 5 g if re-elevated 
aPTT and/or clinically relevant bleeding
*Based on hospital acquisition cost
Praxbind (idarucizumab) prescribing information.
Idarucizumab (Praxbind®)
 RE-VERSE AD study (n=503)
 Predominant sites of bleeding
• GI (45.5%)
• ICH (32.6%)
 Cessation of bleeding
• Median time 2.5 h
 Conclusion
• More than 98% of the patients achieved complete 
and rapid reversal of anticoagulation
• Idarucizumab is effective for patients with 
uncontrolled bleeding or undergoing urgent surgery






 Rash and pruritis
 Monitoring Parameters
 Coagulation parameters 
• aPTT, TT and ECT normalized
 Signs and symptoms of re-bleeding
Praxbind (idarucizumab) prescribing information. 63
Andexanet alfa (Andexxa®) 
 Recombinant modified human factor 
Xa decoy protein 
 Temporary shuts down the activity of 
factor Xa 
 FDA approved May 2018
 Indications (rivaroxaban or apixaban): 
• Life threatening bleeding 
64Andexxa (andexanet alfa) prescribing information.
Andexanet alfa (Andexxa®) 
Dosing regimen
65
Dose Initial IV Bolus Follow-up IV infusion Cost
Low dose 400 mg at a rate of 30 mg/min
4 mg/min for up 
to 120 minutes $25,000*
High dose 800 mg at a rate of 30 mg/min
8 mg/min for up 
to 120 minutes
$50,000*
The safety and efficacy of more than one dose has not been evaluated
*Cost includes bolus plus the follow-up infusion 
*Based on hospital acquisition cost ($2,750 per 100 mg vial)
Andexxa (andexanet alfa) prescribing information.
Andexanet alfa (Andexxa®) 
66
FXa inhibitor Last dose
Timing of FXa Inhibitor 
Last Dose Before 
Andexanet alfa initiation
<8 h or 
unknown
≥8 h
Apixaban < 5 mg Low dose
Low dose
> 5 mg or  
unknown High dose 
Rivaroxaban ≤10 mg Low dose
>10 mg or  
unknown High dose
Andexxa (andexanet alfa) prescribing information.
Andexanet alfa (Andexxa®) 
 ANNEXA-4 Trial (n=67)
 Assessed acute major bleeding within 18 h 
after administration of a factor Xa inhibitor
• GI: 33 patients (49%)
• Intracranial: 28 patients (42%)
• Other: 6 patients (9%)
 Clinical hemostasis
• Reached in 53 patients (79%) 
• 12 h after the end of the infusion
 Conclusion
• Andexanet rapidly reversed anti-factor Xa activity 
Conolly, MD, et al. N Engl J Med. 2016. 67
Andexanet alfa (Andexxa®) 
 Adverse effects
 Urinary tract infections 
 Pneumonia 
 Infusion site reactions
Monitoring
 Signs and symptoms
• Arterial and venous thromboembolic events
• Re-bleeding
• Cardiac arrest
Andexxa (andexanet alfa) prescribing information. 68
Reversal Pipeline
Ciraparantag (PER977®)
 Investigational agent specifically for direct 
thrombin inhibitors, factor Xa inhibitors, 
and heparin (including LMWH)





Gregory YH, et al. CHEST. 2018; 154(5):1121-1201.
Anticoagulation Therapy 2nd edition. ASHP; 2018.
Pharmacist’s Role in Therapy
 Review
 Medication history 
 Laboratory parameters
 Appropriate reversal agent 
 Prevent delays
 Establish protocol for use of reversal agents
 Develop order sets 
 Collaborate with prescribers to determine 
when to restart anticoagulation therapy
70
Pharmacist’s Role in Therapy
 Role in transitions of care
 Assure appropriate therapy
 Ensure medication access 
 Provide patient and caregiver education
 Follow-up is critical in order for patients to 




 First line treatment for
• Stroke prevention in AF patients
• Patients with DVT of the leg or PE and no 
cancer
 Alternative agents for 
• Prophylaxis
 Orthopedic surgical patients 
 Medical patients (hospitalized/non-hospitalized)
72
Take Home Points
 PCC’s are non-hemostatic reversal agents 
used as
 First line for DOACs
 Second line for dabigatran (Pradaxa®)
 Idarucizumab (Praxbind®)
 Specific reversal agent for dabigatran 
(Pradaxa®)
 Andexanet alfa (Andexxa®)
 Specific reversal agent for rivaroxaban 




1. or False: Andexanet alfa (Andexxa®) 
is approved as a reversal agent for 
apixaban (Eliquis®) or rivaroxaban 
(Xarelto®).
2. True or        : The betrixaban (Bevyxxa®) 
dose for atrial fibrillation is 160 mg PO 
twice daily.
3. or False: Direct oral anticoagulants 
(DOACs) may not be used in patients 
with valvular atrial fibrillation.
74
True
False
True
Thank You!
